The study by Annan *et al*. recently published in the *Tropical Medicine and International Health* is, to our knowledge, the first attempt to describe the epidemiology of respiratory infections including Middle East respiratory syndrome coronavirus (MERS‐CoV) among African Hajj pilgrims [1](#tmi12513-bib-0001){ref-type="ref"}. The study sample was representative of the Ghanaian Muslim population. However, there are limitations to the interpretation of their findings.

Intense crowding, close contact and shared accommodation amplify the risk of transmission of respiratory infections among Hajj pilgrims [2](#tmi12513-bib-0002){ref-type="ref"}. Emergence of MERS‐CoV during 2012 in Saudi Arabia and neighbouring countries has raised concern about the risk of global spread of MERS‐CoV from Hajj [3](#tmi12513-bib-0003){ref-type="ref"}. In 2013, the virus spread to a number of countries, including by Umrah performers/returnees [4](#tmi12513-bib-0004){ref-type="ref"}, [5](#tmi12513-bib-0005){ref-type="ref"}. There were several surveillance studies performed at Hajj 2013, referenced by Annan *et al*., but others not been cited even though they add to our understanding [6](#tmi12513-bib-0006){ref-type="ref"}, [7](#tmi12513-bib-0007){ref-type="ref"} (Table [1](#tmi12513-tbl-0001){ref-type="table"}).

###### 

Comparison between respiratory infection studies conducted among Hajj pilgrims in 2013

+----------------------------------+----------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------+---------------------------------------------------------------------------+
| 2013 Hajj studies                | Annan *et al*. [1](#tmi12513-bib-0001){ref-type="ref"}         | Barasheed *et al*. [7](#tmi12513-bib-0007){ref-type="ref"}                                                                      | Benkouiten *et al*. [6](#tmi12513-bib-0006){ref-type="ref"}                          | Memish *et al*. [8](#tmi12513-bib-0008){ref-type="ref"}                   |
+==================================+================================================================+=================================================================================================================================+======================================================================================+===========================================================================+
| Study design                     | Cross‐sectional study (post‐Hajj) (prevalence and attack rate) | Randomised controlled trial (attack rate)                                                                                       | Prospective cohort before and at the end of Hajj (prevalence)                        | Two cross‐sectional studies (pre‐ and post‐Hajj) (prevalence of MERS‐CoV) |
+----------------------------------+----------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------+---------------------------------------------------------------------------+
| Sample size                      | 839                                                            | 1038                                                                                                                            | 129                                                                                  | 5235                                                                      |
+----------------------------------+----------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------+---------------------------------------------------------------------------+
| Place of recruitment             | Kotoka International Airport, Ghana                            | Mina, Greater Makkah                                                                                                            | Marseille, France, Makkah City and Mina                                              | Jeddah Airport                                                            |
+----------------------------------+----------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------+---------------------------------------------------------------------------+
| Participants\' country of origin | Ghana                                                          | Australia, Saudi Arabia and Qatar                                                                                               | France                                                                               | International (from 22 countries)                                         |
+----------------------------------+----------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------+---------------------------------------------------------------------------+
| Age range (mean) in years        | 21--85 (52)                                                    | 18--75 (35)                                                                                                                     | 34--85 (62)                                                                          | 18--93 (52)                                                               |
+----------------------------------+----------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------+---------------------------------------------------------------------------+
| Influenza vaccine uptake         | Not reported                                                   | 69%                                                                                                                             | None received the 2013 influenza vaccine, but 44% received it in the previous season | 22%                                                                       |
+----------------------------------+----------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------+---------------------------------------------------------------------------+
| ILI                              | ILI not reported                                               | 11% (112/1038)                                                                                                                  | 47.3% (61/129)                                                                       | Not reported                                                              |
|                                  |                                                                |                                                                                                                                 |                                                                                      |                                                                           |
|                                  | (77.6% \[651/839\] had respiratory symptoms)                   | ILI was defined as subjective (or proven) fever and at least one respiratory symptom such as cough, sore throat and rhinorrhoea | ILI was defined as the presence of cough, sore throat, and subjective fever          |                                                                           |
+----------------------------------+----------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------+---------------------------------------------------------------------------+
| Swabs type                       | Nasopharyngeal                                                 | Nasopharyngeal                                                                                                                  | Paired nasal and pharyngeal                                                          | Nasopharyngeal                                                            |
+----------------------------------+----------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------+---------------------------------------------------------------------------+
| Laboratory findings              | No MERS‐CoV                                                    | No MERS‐CoV                                                                                                                     | No MERS‐CoV                                                                          | No MERS‐CoV                                                               |
+----------------------------------+----------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------+---------------------------------------------------------------------------+
| Human rhinovirus (HRV)           | Prevalence                                                     | Attack rate                                                                                                                     | Prevalence                                                                           | Not recorded                                                              |
|                                  |                                                                |                                                                                                                                 |                                                                                      |                                                                           |
|                                  | 16.8% (141/839)                                                | 25% (28/112)                                                                                                                    | 14.7% (19/129)                                                                       |                                                                           |
|                                  |                                                                |                                                                                                                                 |                                                                                      |                                                                           |
|                                  | Attack rate                                                    |                                                                                                                                 |                                                                                      |                                                                           |
|                                  |                                                                |                                                                                                                                 |                                                                                      |                                                                           |
|                                  | 17.5% (114/651)                                                |                                                                                                                                 |                                                                                      |                                                                           |
+----------------------------------+----------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------+---------------------------------------------------------------------------+
| Influenza A                      | Prevalence                                                     | Attack rate                                                                                                                     | Prevalence                                                                           | Not recorded                                                              |
|                                  |                                                                |                                                                                                                                 |                                                                                      |                                                                           |
|                                  | 1.3% (11/839)                                                  | 4% (5/112)                                                                                                                      | 7% (9/129)                                                                           |                                                                           |
|                                  |                                                                |                                                                                                                                 |                                                                                      |                                                                           |
|                                  | Attack rate                                                    |                                                                                                                                 |                                                                                      |                                                                           |
|                                  |                                                                |                                                                                                                                 |                                                                                      |                                                                           |
|                                  | 1.1% (7/651)                                                   |                                                                                                                                 |                                                                                      |                                                                           |
+----------------------------------+----------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------+---------------------------------------------------------------------------+
| Influenza B                      | Not studied                                                    | Attack rate                                                                                                                     | Prevalence                                                                           | Not recorded                                                              |
|                                  |                                                                |                                                                                                                                 |                                                                                      |                                                                           |
|                                  |                                                                | 0%                                                                                                                              | 0.8% (1/129)                                                                         |                                                                           |
+----------------------------------+----------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------+---------------------------------------------------------------------------+
| RSV                              | Prevalence                                                     | Attack rate                                                                                                                     | Prevalence                                                                           | Not recorded                                                              |
|                                  |                                                                |                                                                                                                                 |                                                                                      |                                                                           |
|                                  | 5.1% (43/839)                                                  | 0%                                                                                                                              | 0.8% (1/129)                                                                         |                                                                           |
|                                  |                                                                |                                                                                                                                 |                                                                                      |                                                                           |
|                                  | Attack rate                                                    |                                                                                                                                 |                                                                                      |                                                                           |
|                                  |                                                                |                                                                                                                                 |                                                                                      |                                                                           |
|                                  | 1.1% (7/651)                                                   |                                                                                                                                 |                                                                                      |                                                                           |
+----------------------------------+----------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------+---------------------------------------------------------------------------+
| Non‐MERS corona                  | Not studied                                                    | Attack rate                                                                                                                     | Prevalence                                                                           | Not recorded                                                              |
|                                  |                                                                |                                                                                                                                 |                                                                                      |                                                                           |
|                                  |                                                                | 2% (2/112)                                                                                                                      | 20.9% (27/129)                                                                       |                                                                           |
|                                  |                                                                |                                                                                                                                 |                                                                                      |                                                                           |
|                                  |                                                                | (OC43 and 229E)                                                                                                                 | (16 229E, 5 OC43, 5 HKU1 and 1 NL63)                                                 |                                                                           |
+----------------------------------+----------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------+---------------------------------------------------------------------------+
| Parainfluenza                    | Not studied                                                    | Attack rate                                                                                                                     | Prevalence                                                                           | Not recorded                                                              |
|                                  |                                                                |                                                                                                                                 |                                                                                      |                                                                           |
|                                  |                                                                | 2.7% (3/112)                                                                                                                    | 0.8% (1/129)                                                                         |                                                                           |
+----------------------------------+----------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------+---------------------------------------------------------------------------+
| Dual viral infection             | Prevalence                                                     | Attack rate                                                                                                                     | Nil                                                                                  | Not relevant                                                              |
|                                  |                                                                |                                                                                                                                 |                                                                                      |                                                                           |
|                                  | 1.9% (16/839)                                                  | 2% (2/112)                                                                                                                      |                                                                                      |                                                                           |
|                                  |                                                                |                                                                                                                                 |                                                                                      |                                                                           |
|                                  | (14 RSV/HRV and 2 Flu A/HRV)                                   | (HRV/adenovirus and HRV/coronavirus)                                                                                            |                                                                                      |                                                                           |
+----------------------------------+----------------------------------------------------------------+---------------------------------------------------------------------------------------------------------------------------------+--------------------------------------------------------------------------------------+---------------------------------------------------------------------------+
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Studies conducted at Hajj 2013 varied in their methods, study population and sample size, perhaps influencing outcomes. Memish *et al*. [8](#tmi12513-bib-0008){ref-type="ref"} and Annan *et al*. [1](#tmi12513-bib-0001){ref-type="ref"} recruited, respectively, 5235 and 839 people but provided only airport‐based surveillance data. In contrast, studies by Barasheed *et al*. [7](#tmi12513-bib-0007){ref-type="ref"} and Benkouiten *et al*. [6](#tmi12513-bib-0006){ref-type="ref"} were conducted at the main Hajj locations (Makkah and Mina) during the peak period of Hajj with daily follow‐up. Benkouiten *et al*. followed one Hajj travel group (*n* = 129) from Marseille, France, and studied an array of microorganisms including bacteria and uncommon viruses, whereas Barasheed *et al*. selected participants from several travel groups who developed respiratory symptoms; they were closely followed up in a large trial (*n* = 1038) involving Saudi Arabian, Australian and Qatari pilgrims.

All these 2013 studies involved testing nasopharyngeal or nasal samples for MERS‐CoV (Benkouiten *et al*. additionally obtained throat swabs), which are less sensitive in detecting MERS‐CoV (Table [1](#tmi12513-tbl-0001){ref-type="table"}); lower respiratory tract samples such as bronchoalveolar lavage and tracheal aspirates result in higher yields [9](#tmi12513-bib-0009){ref-type="ref"}; therefore, Annan *et al*.\'s notion that there is 'no evidence of MERS‐CoV in Hajj pilgrims returning to Ghana, 2013' sounds overenthusiastic [1](#tmi12513-bib-0001){ref-type="ref"}.

Most studies reported participants\' respiratory symptoms; the most commonly reported symptoms were cough, sore throat and fever. Barasheed *et al*. [7](#tmi12513-bib-0007){ref-type="ref"} and Benkouiten *et al*. [6](#tmi12513-bib-0006){ref-type="ref"} reported the prevalence of influenza‐like illness (ILI) among their participants to be 11% and 47%, respectively, but Annan *et al*. [1](#tmi12513-bib-0001){ref-type="ref"} did not provide the prevalence of ILI. One caveat is that the definition of ILI differed between the studies (Table [1](#tmi12513-tbl-0001){ref-type="table"}). The attack rate of laboratory‐proven influenza in Annan *et al*.\'s study was lower than in other studies (Benkouiten *et al*. and Barasheed *et al*.) (Table [1](#tmi12513-tbl-0001){ref-type="table"}). This could be influenced by differences in influenza vaccine uptake. For instance, none of the French recruits received the 2013 influenza vaccine, while 69% of the participants in Barasheed *et al*.\'s study did. The rate of influenza A was 7% and 4%, respectively [6](#tmi12513-bib-0006){ref-type="ref"}, [7](#tmi12513-bib-0007){ref-type="ref"}. Annan *et al*. [1](#tmi12513-bib-0001){ref-type="ref"} reported an attack rate for influenza of 1.1%, but did not provide influenza vaccination data. Of interest, influenza was circulating in tropical Africa during the Hajj 2013 [10](#tmi12513-bib-0010){ref-type="ref"}.

Thirdly, Annan *et al*. reported that the prevalence of RSV among returned Ghanaian pilgrims was 5.1% (attack rate 1.1) and contrasted that with Benkouiten\'s prevalence of 0.8% among French pilgrims. However, the higher rate of RSV reported by Annan *et al*. is not unexpected; a higher attack rate of 9% was reported among returned symptomatic UK pilgrims after the Hajj 2005 [11](#tmi12513-bib-0011){ref-type="ref"}. Rashid *et al*. also showed that during the same year the attack rate of RSV among UK pilgrims in Makkah was 4% [12](#tmi12513-bib-0012){ref-type="ref"}. By contrast, during the subsequent Hajj season, the attack rate of RSV was very low (0.7%) among UK pilgrims and zero among Saudi pilgrims [13](#tmi12513-bib-0013){ref-type="ref"} indicating that the circulation of RSV is dependent on various factors such as seasonality, geographical original of the pilgrims and their close association with children.

Absence of MERS‐CoV in nasal or nasopharyngeal samples of pilgrims does not rule out risk of the disease at Hajj. A recent estimate suggests that MERS‐CoV has a basic reproduction number (R0) similar to that of SARS, that is 2--6.7 [14](#tmi12513-bib-0014){ref-type="ref"}, but mathematical modelling studies indicate that the risk of an outbreak is low [15](#tmi12513-bib-0015){ref-type="ref"}. Considering the increasing number of Umrah pilgrims in the forthcoming months when the likelihood of a MERS‐CoV upsurge is high due to the seasonal pattern of the disease [16](#tmi12513-bib-0016){ref-type="ref"}, surveillance must continue. Accordingly, we continued our study in 2014 and recruited over 2000 pilgrims from Gulf countries and Australia. Preliminary findings suggest that of 298 Australian pilgrims, only two (0.7%) had symptoms of severe respiratory infection, but none had pneumonia. Virological testing will provide further data on the epidemiology of respiratory viruses among Hajj pilgrims. Ongoing active surveillance is mandatory to better understand transmission dynamics of MERS‐CoV.

The study conducted by our team [7](#tmi12513-bib-0007){ref-type="ref"} was made possible by a National Priorities Research Program grant from the Qatar National Research Fund (a member of Qatar Foundation).
